- Published: 20 November 2013
- Written by Editor
ERBA Diagnostics, Inc. Exhibits at MEDICA 2013, Dusseldorf Germany “World Forum for Medicine”
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, is pleased to announce that it will be exhibiting its full range of products at the World's largest medical show, MEDICA 2013 in Dusseldorf Germany Nov. 20-23.
While ERBA group will be showcasing its entire product range from its Global Subsidiaries that include the Elisa range for Auto Immune and Infectious Disease, Chemistry Analyzers, Hematology analyzers, Urine Analyzers and Coagulation systems along with the wide range of reagent kits we offer, we are particularly excited about the launching of two new high tech product offerings – the Laura XL and Hb–Vario.
The Laura XL is a fully automated Urinalysis and sedimentation processor with the capability to automate Urine strip reading as well as performing sedimentation cell analysis for abnormal samples. The estimated IVD Urinalysis market is approximately $600 Million USD per year.
ERBA will also be showcasing the Hb-Vario, an automated HPLC system that is capable of measuring both HbA1c/ and A2 for the monitoring of diabetes. Diabetes continues to be one of the major challenges worldwide to the healthcare industry. The benefits of monitoring A1c values to better manage diabetes is well documented in numerous studies. The measurement control of A1c values is key to reducing co-morbidity complications within this population.
Glycated hemoglobin (HbA1c) testing is poised to emerge as a popular technology with outpatient clinics and other small hospital-based laboratories according to a Global Industry Analyst report. The same report also forecasts that the global market for Diabetes Diagnostics is estimated to reach US$26 billion by the year 2015. Bio-Rad and Tosoh are the market leaders in this segment. Diabetes testing is a focus area for growth for ERBA.
With the launching of these two exciting products, ERBA expects to further grow its existing global market share in these two segments.
ERBA is now strongly focused on new product developments and looks forward to the ever increasing product portfolio to serve the health care providers and patients worldwide.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, through its three subsidiaries: Diamedix Corporation (U.S.), Delta Biologicals S.r.L. (Europe) and ImmunoVision, Inc. (U.S.).
Mohan Gopalkrishnan, 305-989-0866
